ArticleMedicine2019

CD56-chimeric antigen receptor T-cell therapy for refractory/recurrent rhabdomyosarcoma: A 3.5-year follow-up case report.

Chiyi Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.